CORT — Corcept Therapeutics Incorporated Share News
0.000.00%
Last trade - 00:00- $12.26bn
- $11.94bn
- $761.41m
Brief: Overall Survival Primary Endpoint Met In Corcept’S Pivotal Phase 3 ROSELLA Trial Of Relacorilant In Patients With Platinum-Resistant Ovarian Cancer
Corcept's cancer drug meets main goal in late-stage trial
U.S. RESEARCH ROUNDUP-Axsome Therapeutics, Block, Terawulf
Corcept drops after US FDA declines to approve drug for rare hormonal disorder
NASDAQ RESUMED AT 08:20 AM
US FDA declines to approve Corcept's drug for rare hormonal disorder (updated)
Brief: Corcept Receives Complete Response Letter For Relacorilant As A Treatment For Patients With Hypercortisolism
US FDA declines to approve Corcept's drug for rare hormonal disorder
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
Corcept Therapeutics misses Q3 revenue expectations, modifies 2025 revenue forecast
Brief: Corcept Therapeutics Q3 EPS USD 0.16
Brief: Corcept Therapeutics Inc - Terminates Distribution Agreement With Optime Care - SEC Filing
Drugmaker Corcept must face Teva lawsuit over mifepristone 'monopoly' for rare disorder
Brief: FDA Reviews Corcept’s NDA for Relacorilant in Drug-Resistant Ovarian Cancer
U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Amazon, Appfolio
Corcept Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Corcept Therapeutics Q2 EPS USD 0.29
Corcept Therapeutics Inc expected to post earnings of 19 cents a share - Earnings Preview
Brief: Corcept Therapeutics To Announce Second Quarter Financial Results